Lung cancer is often at its most difficult to treat by the time it becomes noticeable. Symptoms can signal that the disease has already progressed, leaving patients with fewer opportunities for potentially curative treatment.
That makes early identification especially important for people whose risk is already known.
For our primary care team, at Primary Medical Care Center in Miami, lung cancer screening is therefore about more than ordering a scan. It is about recognizing which patients may benefit from screening, having a meaningful conversation about the risks and benefits, helping them overcome practical barriers, and making sure abnormal results lead to the right next step.
A proactive approach can move lung cancer care away from a model that waits for symptoms and toward one that looks for disease before it becomes a crisis.
Why Finding Lung Cancer Before Symptoms Matters
Early-stage lung cancer can sometimes be treated with curative intent, including through surgery or stereotactic body radiation therapy (SBRT). The challenge is that many patients are not diagnosed until after symptoms have appeared.
According to the source article, only 21% of lung cancers are localized when diagnosed. That makes identifying people at elevated risk and screening them before symptoms develop an important part of preventive care.
Primary care is particularly well suited to this work because risk assessment can happen as part of routine care. A provider and care team can look at a patient’s smoking history, age, and overall health; discuss screening before symptoms emerge; and help the patient understand what the process involves.
The goal isn’t simply to find more abnormalities. It is to identify appropriate patients early enough that meaningful treatment options remain available.
Low-Dose CT Is the Key Screening Tool
For people who meet established high-risk criteria, low-dose computed tomography (LDCT) is the standard screening method discussed in the source article. Unlike a conventional chest X-ray, LDCT can identify smaller abnormalities in the lungs and has demonstrated a survival advantage in large studies.
The eligibility criteria outlined are
- Age 50 to 80
- At least 20 pack-years of smoking history
- Currently smoking or having quit within the previous 15 years
A pack-year represents smoking one pack of cigarettes per day for one year. Someone who smoked two packs per day for 10 years, for example, would have 20 pack-years.
Screening is generally discontinued once a person reaches 81, has been smoke-free for 15 years, or develops a condition that substantially limits life expectancy or the ability or willingness to undergo curative treatment.
For eligible patients, the important point is timing: screening is intended for people who may not have symptoms yet.
A Screening Program Cannot End When the Scan Is Finished
One of the biggest misconceptions about cancer screening is that the screening event itself is the entire process.
It isn’t.
An LDCT may reveal a lung nodule that turns out to be harmless. Conversely, an early cancer may not initially look suspicious. Minimal cancers can also escape detection. And because LDCT uses ionizing radiation, screening itself involves a small exposure that should be considered as part of the decision-making process.
Then there is the uncertainty that can follow an abnormal finding.
Depending on what the scan shows, a patient may need:
- Another CT scan,
- PET/CT imaging,
- A biopsy,
- Specialist evaluation,
- Additional surveillance, or
- Treatment.
For a patient, that sequence can be confusing and stressful. A suspicious nodule doesn’t automatically mean cancer, but waiting to find out what it means can create considerable anxiety.
Such uncertainty is why effective screening requires continuity.
Our primary care team in Miami can help patients understand their results, keep track of recommended follow-up, coordinate referrals, and make sure an abnormal screening result does not disappear into the healthcare system.
The Real Challenge Is Often Getting the Right Patient Through the Entire Process
Identifying an eligible patient is only the beginning.
Older adults may face practical obstacles that make screening difficult. Transportation can be unreliable. Medical information may be difficult to understand. Appointments may need to be coordinated across several providers. And follow-up after an abnormal scan may be inconsistent.
Each individual barrier may seem manageable. Together, however, they can cause a patient to miss a screening appointment or delay follow-up.
That can turn an opportunity for early detection into another delayed diagnosis.
A proactive primary care team can address these obstacles before they become reasons for a patient to fall out of care. Screening can be discussed during routine visits rather than waiting for a separate initiative. Staff can help coordinate appointments, explain results in understandable language, and, when appropriate, involve family members or caregivers.
Trust matters, too.
A patient is more likely to participate when they understand why screening has been recommended, what the scan can and cannot tell them, what happens afterward, and who will help them navigate the results.
Smoking Cessation Belongs in the Same Conversation
Lung cancer screening and smoking cessation should not be treated as unrelated activities.
For patients who continue to smoke, a screening discussion creates another opportunity to address tobacco use and connect them with cessation resources.
Screening does not eliminate the underlying risk associated with smoking. Instead, it provides an opportunity to identify disease earlier while also addressing one of the most important modifiable risk factors.
This is another reason primary care is central to lung cancer prevention: the same care team can identify risk, recommend appropriate screening, and support broader efforts to improve the patient’s health.
Technology Could Expand What Early Detection Makes Possible
LDCT remains the established screening approach for high-risk patients, but researchers are investigating technologies that could eventually complement or improve current strategies.
Among the approaches being studied are liquid biopsies, which look for potential cancer-related signals in the blood. Research has explored biomarkers, including:
- circulating cell-free DNA,
- microRNA,
- circulating tumor cells,
- tumor-derived exosomes, and
- tumor-educated platelets.
Researchers are also investigating breath-based testing, including the analysis of volatile organic compounds.
Artificial intelligence is another area of interest. AI-based systems may eventually help clinicians combine information from medical histories, imaging, and laboratory data to produce more individualized assessments of cancer risk.
AI-enhanced LDCT and multi-omics approaches could potentially help identify disease earlier and reduce unnecessary false-positive results.
But these technologies should be viewed as additions to clinical care rather than replacements for it.
A sophisticated screening tool still needs a healthcare professional who can explain what the result means, determine what happens next, and understand the patient’s broader circumstances.
Value-Based Primary Care Can Turn Screening Into a Continuous Process
The difference between a reactive and proactive approach becomes particularly clear with lung cancer.
A reactive system waits for symptoms, investigates a problem, and responds once disease has become apparent.
A proactive system asks a different question:
Who is at risk right now, and what can we do before that risk becomes a diagnosis?
For lung cancer, that means identifying eligible patients before symptoms appear, discussing LDCT, helping them complete the scan, and staying involved after the results arrive.
It also means recognizing that patients do not experience healthcare as a collection of isolated appointments. A screening scan, a smoking-cessation discussion, a specialist referral, and a follow-up CT may all be parts of the same care journey.
Coordinating those pieces can make screening more accessible and less intimidating while reducing the possibility that an important follow-up step is missed.
Closing the Gap Before Lung Cancer Becomes a Crisis
The value of lung cancer screening is not simply that it can detect cancer.
Its greater value is that it can create time to identify disease before symptoms appear, time to investigate suspicious findings, and, when appropriate, time to pursue treatment while curative options may still be available.
Primary care teams are in a unique position to create that opportunity.
They can identify high-risk patients, explain why screening matters, arrange LDCT, address transportation and other barriers, support smoking cessation, and remain involved when the scan produces an abnormal result.
That approach changes the role of primary care from reacting to illness to actively searching for opportunities to prevent delayed diagnosis.
Primary Medical Care Center offers personalized holistic care to handle lung cancer more effectively and in a more conducive environment. Call (305) 751-1500 for an appointment today!